Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

L.A. McKeown

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Caitlin E. Cox

July 30, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Caitlin E. Cox

February 07, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

L.A. McKeown

September 11, 2017

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Caitlin E. Cox

February 07, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

L.A. McKeown

September 22, 2016

News Daily News

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Caitlin E. Cox

July 07, 2016

News Daily News

Large Meta-analysis Supports Radial as Default Approach in All CAD Types

L.A. McKeown

July 06, 2016

News Daily News

Meta-Analysis Boosts Case for Increased Use of Radial Access

November 29, 2015

Advertisement

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

FDA’s First Take on New Paclitaxel Concerns in CLI

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

TCTMD’s Top 10 Most Popular Stories for January 2019

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Veryan Medical receives PMA approval for BioMimics 3D

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Large Meta-analysis Supports Radial as Default Approach in All CAD Types

Meta-Analysis Boosts Case for Increased Use of Radial Access

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content